Orally available transition state inhibitors for triple negative breast cancer

  • Isaacman, Steven (PI)
  • Schramm, Vern L. (CoPI)
  • Rose, Susan A. (PI)
  • Rose, Susan A. (PI)

Project: Research project

Project Details

Description

Problem to be Solved: Triple-negative breast cancer (TNBC) is a deadly disease that accounts for 15-20% of all diagnosed breast cancers worldwide. Metastatic relapse of TNBC carries a poorer prognosis and lower survival rate compared to other breast cancersubtypes. Therefore, identifying novel targets and new therapeutics to treat patients diagnosed with TNBC remains a significant priority of the National Institutes of Health. Product and Long-Term Goal: Nanometics is developing a once daily, oral therapeutic, dubbed MTDIA for the treatment of TNBC. MTDIA inhibits a novel target, 5 -methylthioadenosine phosphorylase (MTAP), and disrupts biochemical pathways crucial for cancer growth. Technical Innovation: The MTAP enzyme is a promising new target for anti-cancer therapeutics because its systemic inhibition results in the whole-body accumulation of the 5'-methylthioadenosine (MTA) metabolite, which alters known anti-cancer pathways. Oral dosing with MTDIA is effective against both MTAP-positive and MTAP-n

StatusFinished
Effective start/end date1/1/146/30/16

Funding

  • National Cancer Institute: $225,000.00

ASJC

  • Oncology
  • Cancer Research
  • Medicine(all)

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.